Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Executive VP & CCO | January 03, 2019 | January 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
Verastem, Inc.
Report date January 03, 2019 · Filed January 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2029-01-03 | Direct | 62,500 |
Reported balance
After 2019-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-03 · Grant · Acquired 62,500 · Balance 62,500 F1: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2029-01-03 | Direct | 62,500 |
Reported balance
After 2019-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-03 · Grant · Acquired 62,500 · Balance 62,500 F2: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
F2: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001536193-26-000002 · form4-06092026_080653.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:00 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001536193-25-000004 · form4-12292025_101215.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-12-23 F1 · derivative.exercise_date: The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-25-016467 · form4-06102025_080614.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001415889-24-016216 · form4-06102024_080623.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:37 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036470 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 8, 2023, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2024 annual stockholders meeting or June 8, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:02 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-22-035206 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:04 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $18.21 | $0.00 |
DisclosureSEC source: 0001209191-21-038682 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 21:27 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001209191-20-035028 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option is fully vested on June 5, 2021, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038101 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:48 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-19-000028 · edgar.xml · derivative · entry 2 Lobacki Joseph M · CIK 0001536193 · Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2029-01-03 F2 · derivative.exercise_date: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:48 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-19-000028 · edgar.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2029-01-03 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 23:11 UTC | Verastem, Inc. VSTM · Entity 5242 | PurchaseCommon Stock | 3,000 | $7.30 | $21,900.00 |
DisclosureSEC source: 0000904454-18-000633 · edgar.xml · nonDerivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 22:01 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 26,033 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052490 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,033 Underlying: Common Stock · 26,033 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:58 UTC | Verastem, Inc. VSTM · Entity 5242 | PurchaseCommon Stock | 7,700 | $5.79 | $44,583.00 |
DisclosureSEC source: 0001104659-18-039657 · a4.xml · nonDerivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,700 Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:26 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001104659-18-000988 · a4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: 25% of this option will vest on January 3, 2019 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 3, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.